| Literature DB >> 28428948 |
Saira R Martínez-Alemán1, Lizbeth Campos-García1, José P Palma-Nicolas1, Romel Hernández-Bello1, Gloria M González1, Alejandro Sánchez-González1.
Abstract
Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the gene that codes for the CF trans-membrane conductance regulator. These mutations result in abnormal secretions viscous airways of the lungs, favoring pulmonary infection and inflammation in the middle of neutrophil recruitment. Recently it was described that neutrophils can contribute with disease pathology by extruding large amounts of nuclear material through a mechanism of cell death known as Neutrophil Extracellular Traps (NETs) into the airways of patients with CF. Additionally, NETs production can contribute to airway colonization with bacteria, since they are the microorganisms most frequently found in these patients. In this review, we will discuss the implication of individual or mixed bacterial infections that most often colonize the lung of patients with CF, and the NETs role on the disease.Entities:
Keywords: Burkholderia cepacia; CFTR; NETs; Pseudomonas aeruginosa; Staphylococcus aureus; cystic fibrosis; neutrophil
Mesh:
Year: 2017 PMID: 28428948 PMCID: PMC5382324 DOI: 10.3389/fcimb.2017.00104
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Classes of CFTR mutations that cause cystic fibrosis.
| I | About half of the CFTR mutations are expected to prevent proper synthesis of full-length, normal CFTR polypeptide because of nonsense, frameshift, or aberrant splicing of mRNA. | G542X | Rowe et al., |
| II | The defective protein retains substantial chloride-channel function in cell-free lipid membranes. When synthesized by the normal cellular machinery, however, the protein is rapidly recognized as misfolded and is degraded shortly after synthesis, before it can reach its crucial site of action at the cell surface. | ΔF508 | O'Sullivan and Freedman, |
| III | It encodes properly processed, full-length CFTR protein that lacks normal ion-channel activity | G551D | Rowe et al., |
| IV | This mutation exhibits only partial CFTR ion-channel activity, a feature that probably explains a less severe pulmonary phenotype. | A455E | Gan et al., |
| V | It includes promoter mutations that reduce transcription, nucleotide alterations that promote alternative splicing of the CFTR transcript, and amino acid substitutions that cause inefficient protein maturation. | P574H | Welsh and Smith, |
Figure 1NET formation in the lung surface of cystic fibrosis patients. Implications on disease prognosis (text box) in bacterial single infections (middle panel) and coinfections (lower panel) are shown. NET formation can constitute a scaffold for the establishment of simple infections or coinfections that can directly influence the elimination of pathogens that have direct repercussions on patient's health. Upper panel, within single infections, P. aeruginosa is the main bacterium that colonizes the lungs of patients with cystic fibrosis, and is associated with decreased microbiome as compared to healthy individuals. Patients colonized with B. cepacia are at higher risk of developing septicemia by decreasing their life expectancy. On the other hand, S. aureus is less aggressive compared to P. aeruginosa and B. cepacia, despite this, it can decrease lung function and increase the mortality rate. Bottom panel, mixed infections caused by P. aeruginosa and B. cepacia may become the most aggressive, due to a rapid loss of lung function, increasing the risk of pulmonary exacerbation and mortality. Coinfections between P. aeruginosa and S. aureus, have a very antagonistic interaction in which they compete for their establishment by decreasing the rate of acquisition and the rate of loss of another, such battle promote increased lung damage and rapid worsening of patient's health. On the other hand, coinfections between P. aeruginosa, S. aureus, and B. cepacia causes progressive lung disease and decreased lung function severely compromising patients' health.